FIELD: medicine, pharmaceutics.
SUBSTANCE: what is presented is the use of L-carnosine for making a nanopreparation having antihypoxic and antioxidant activity combined with a combination of substances selected from the group of phospholipids, non-polar lipids in the following ratio, wt %: L-carnosine - 1.1-1.2, non-polar lipids such as triglycerides, cholesterol, free fatty acids, DL-α-Tocopherol - 1.2-2.5, phospholipids such as phosphatidylcholine, phosphatidylethanolamine, lysophosphatidylcholine, lysophosphatidylethanolamine, sphingomyelin - 95.3-96.3 for preparing a drug having antihypoxic and antioxidant activity. The drug can be presented in the form of liposomes containing L-carnosine.
EFFECT: invention provides higher stability of L-carnosine and its lifetime up to three days with underlying higher effectiveness in small doses, as well as to improve the cerebral ischemia tolerance, the recovery after acute hypoxia and to increase the antioxidant status of the brain tissue.
3 cl, 4 dwg
Title | Year | Author | Number |
---|---|---|---|
LIPOSOME COMPOSITION CONTAINING SELEGILIN, METHOD OF PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION WITH MONOAMINOOXIDASE- INHIBITING ACTIVITY | 1995 |
|
RU2159106C2 |
AGENT SHOWING ANTIHYPOXIC AND ANTIOXIDANT ACTIVITY | 2001 |
|
RU2191592C1 |
COMPOSITION OF DIHYDROQUERCETINE ENCLOSED IN PHOSPHOLIPID NANOPARTICLES | 2013 |
|
RU2536208C1 |
LIPOIC ACID MYCELIAL COMPLEX WITH CARNOSINE FOR MAMMALS PROTECTION AGAINST OXIDATIVE STRESS | 2016 |
|
RU2647435C2 |
AGENT WITH LIPOSOMES CONTAINING GLUTAMIC ACID AND PROPOLIS EXTRACT, EXHIBITING NOOTROPIC ACTIVITY | 2015 |
|
RU2589280C1 |
NATURAL PHOSPHOLIPID AGENT | 2008 |
|
RU2367443C1 |
PARKINSON'S DISEASE TREATMENT MODE | 2007 |
|
RU2353382C1 |
TOLL-LIKE RECEPTOR 7 OR 8 AGONIST AND CHOLESTEROL COMPLEX AND ITS USE | 2020 |
|
RU2790702C1 |
FUNCTIONAL FOOD PRODUCT | 2008 |
|
RU2370158C1 |
LIPOSOMAL COMPOSITIONS USED FOR DRUG DELIVERY | 2015 |
|
RU2757110C2 |
Authors
Dates
2013-05-27—Published
2012-03-20—Filed